TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 163.75%.
Alto crecimiento de los beneficios
Los ingresos netos de la empresa lideran el sector. Sus ingresos anuales más recientes ascienden a 616.29M USD.
Valorada de forma justa
El PE más reciente de la empresa es 17.42, en un rango percentil medio de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 122.50M acciones, lo que supone un aumento del 3.47% con respecto al trimestre anterior.
En posesión de Ray Dalio
El inversor estrella Ray Dalio posee 264.03K acciones de este valor.